Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.1% in October

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) was the target of a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 528,200 shares, a decline of 18.1% from the October 15th total of 644,700 shares. Based on an average trading volume of 159,300 shares, the days-to-cover ratio is presently 3.3 days. Approximately 2.1% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, William Blair upgraded shares of Vistagen Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th.

Vistagen Therapeutics Trading Down 3.7 %

Shares of VTGN stock opened at $2.63 on Friday. Vistagen Therapeutics has a 12 month low of $2.58 and a 12 month high of $5.86. The company has a market capitalization of $73.22 million, a P/E ratio of -2.12 and a beta of 0.78. The stock has a 50 day moving average of $3.04 and a two-hundred day moving average of $3.49.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.06. The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.30 million. Vistagen Therapeutics had a negative net margin of 4,521.71% and a negative return on equity of 36.35%. During the same quarter in the previous year, the firm posted ($0.94) EPS. Sell-side analysts predict that Vistagen Therapeutics will post -1.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC acquired a new stake in Vistagen Therapeutics during the first quarter valued at approximately $169,000. Blair William & Co. IL boosted its stake in Vistagen Therapeutics by 29.2% in the 2nd quarter. Blair William & Co. IL now owns 88,466 shares of the company’s stock valued at $308,000 after buying an additional 20,000 shares in the last quarter. American Century Companies Inc. grew its position in Vistagen Therapeutics by 49.1% in the second quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock valued at $105,000 after acquiring an additional 9,984 shares during the period. Jane Street Group LLC acquired a new position in Vistagen Therapeutics during the third quarter worth $59,000. Finally, HighTower Advisors LLC bought a new position in shares of Vistagen Therapeutics during the third quarter valued at $64,000. Institutional investors and hedge funds own 78.39% of the company’s stock.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.